Table 3.
Determination of prognostic clinical factors
| Clinical characteristics | Training set (N = 151) |
Uni-variables cox | Multi-variables cox | ||||
|---|---|---|---|---|---|---|---|
| HR | 95%CI | P-value | HR | 95%CI | P-value | ||
| Age (years, mean ± SD) | 59.82 ± 13.67 | 1.029 | 1.014–1.045 | 1.966 × 10− 04 | 1.022 | 1.005–1.039 | 1.310 × 10−02 |
| Gender (Male/Female) | 97/54 | 0.899 | 0.613–1.320 | 5.886 × 10−01 | – | – | – |
| Chemo-therapy (Yes/No/−) | 45/89/17 | 0.603 | 0.397–0.915 | 1.625 × 10− 02 | 1.791 | 0.895–3.585 | 9.960 × 10− 02 |
| Drug-therapy (Yes/No/−) | 20/113/18 | 0.729 | 0.431–1.234 | 2.377 × 10−01 | – | – | – |
| Immuno-therapy (Yes/No/−) | 2/131/18 | 0.555 | 0.136–2.264 | 4.050 × 10−01 | – | – | – |
| Pharmaceutical-therapy (Yes/No/−) | 55/82/14 | 0.419 | 0.276–0.639 | 3.239 × 10−05 | 0.335 | 0.169–0.663 | 1.700 × 10−03 |
| Targeted molecular-therapy (Yes/No/−) | 18/115/18 | 0.889 | 0.519–1.523 | 6.701 × 10−01 | – | – | – |
| Radiotherapy (Yes/No/−) | 20/117/14 | 0.611 | 0.346–1.078 | 8.575 × 10−02 | – | – | – |
| Risk status (High/Low) | 75/76 | 4.519 | 2.963–6.894 | 4.319 × 10−14 | 4.179 | 2.631–6.640 | 1.390 × 10−09 |
| Dead (Death/Alive/−) | 115/36 | – | – | – | – | – | – |
| Overall survival time (months, mean ± SD) | 13.26 ± 10.82 | – | – | – | – | – | – |
SD Standard deviation, HR Hazard ratio, CI Confidential interval